Welcome to our dedicated page for Phreesia news (Ticker: PHR), a resource for investors and traders seeking the latest updates and insights on Phreesia stock.
Phreesia, Inc. (symbol: PHR) is a leading provider of comprehensive software solutions designed to enhance the operational and financial performance of healthcare organizations. Through its innovative SaaS-based technology platform, Phreesia enables medical groups of all sizes to streamline their administrative, financial, and clinical operations, thereby allowing healthcare staff to focus more on delivering exceptional patient care.
The Phreesia Platform offers a robust suite of integrated solutions that manage various aspects of patient interactions. These solutions include patient access, registration, payments, and clinical support, all aimed at optimizing patient health outcomes. By activating patients in their care, Phreesia ensures that healthcare providers can offer more personalized and efficient services.
Phreesia's flexible and scalable platform is trusted by leading healthcare organizations to revolutionize their point of service. The platform encompasses a wide range of technologies and services, from initial patient contact and registration to appointment scheduling, payment processing, and post-appointment patient surveys. This comprehensive range of services drives tangible results, enhancing both patient and provider experiences.
Recent achievements and current projects at Phreesia include continuous updates to their software to ensure compatibility with the latest technological advancements and regulatory requirements. The company also focuses on forming strategic partnerships that further enhance the capabilities of their platform.
In terms of financial condition, Phreesia has shown consistent growth, driven by the increasing demand for efficient healthcare management solutions. The company's ability to adapt to the evolving needs of the healthcare industry makes it a significant player in the market.
Phreesia (NYSE: PHR) has announced the release date for its fiscal second quarter 2025 financial results. The company will publish its quarterly results and stakeholder letter after market close on Wednesday, September 4, 2024. A conference call to discuss the results will follow at 5 PM Eastern Time. Investors can participate by dialing (800) 715-9871 (US) or (646) 307-1963 (international) using code 7404611. The call will also be available via webcast on Phreesia's investor website.
Phreesia, founded in 2005, is a leader in patient activation, providing tools for healthcare providers, life sciences companies, and payers. In 2023, the company facilitated approximately 150 million patient visits, representing over 10% of U.S. healthcare visits. Phreesia offers digital solutions for patient intake, outreach, and education to enhance patient experience and improve healthcare outcomes.
Phreesia, a leader in patient intake and activation, has announced its availability on Oracle Healthcare Marketplace, integrating with Oracle Health Electronic Health Record (EHR). This collaboration enhances Phreesia's existing integration with Oracle, offering expanded benefits for customers. Organizations using Oracle Health EHR can now leverage Phreesia's suite of solutions, including appointment scheduling, patient registration, consent management, revenue cycle management, clinical intake workflows, and referral management.
Phreesia has achieved Oracle's Industry Healthcare Expertise validation, highlighting its commitment to serving Oracle Health customers. In 2023, Phreesia enabled approximately 150 million patient visits, representing more than 1 in 10 visits across the U.S. This integration aims to enhance patient experience, drive efficiency, and improve healthcare outcomes.
Phreesia, in collaboration with the National Kidney Foundation, has published new research in The American Journal of Accountable Care, highlighting the importance of patient-provider discussions and patient activation for the early diagnosis and treatment of chronic kidney disease (CKD). The study surveyed 4,445 patients with diabetes and/or hypertension and revealed that two-thirds of these high-risk patients were unaware of their risk for CKD. Key findings showed that 70% of highly activated diabetic patients discussed kidney health with their provider, compared to 38% of low-activation patients. Similarly, 51% of highly activated hypertensive patients had these discussions compared to just 7% of their low-activation counterparts. The research emphasizes that patient activation and frequent patient-provider conversations are vital in encouraging preventive health behaviors. Phreesia's ability to deliver personalized messages at the point of care aims to improve patient awareness and engagement, potentially leading to better health outcomes.
Phreesia (NYSE: PHR) reported its financial results for the fiscal first quarter ending April 30, 2024. The company achieved total revenue of $101.2 million, marking a 21% increase year-over-year. The average number of healthcare services clients (AHSCs) grew by 23% year-over-year to 4,065.
Healthcare services revenue per AHSC declined by 3% to $18,243, and total revenue per AHSC fell by 2% to $24,900. Net loss narrowed to $19.7 million from $37.5 million in the same period last year. Adjusted EBITDA turned positive at $4.1 million compared to a negative $13.8 million.
Cash and cash equivalents stood at $79.5 million, a decrease of $8 million from January 31, 2024. The company revised its fiscal year 2025 revenue outlook to $416-$426 million, down from the previous $424-$434 million, due to the wind-down of a clearinghouse client relationship.
However, Phreesia raised its Adjusted EBITDA guidance to $21-$26 million from $12-$20 million, citing better margin improvements and a focus on profitability.
Phreesia, a leader in patient intake and activation, has joined the MEDITECH Alliance Program as an Innovator Partner. This partnership allows MEDITECH customers to utilize Phreesia's patient-driven registration solutions in both hospital and ambulatory care settings. Phreesia will provide embedded solutions within MEDITECH as a Service (MaaS) and deliver integrated solutions for all Expanse customers. This collaboration began with Phreesia's acquisition of Access eForms in 2023. The partnership aims to enhance patient engagement, streamline operations, and improve financial health for healthcare systems. Phreesia's automated workflows are designed to reduce staffing burdens and boost efficiency.
Phreesia announced that Amy Patel, its Director of Analytics, has been named one of PM360's 2024 ELITE 100. These awards recognize influential individuals in healthcare and life sciences.
Patel has over 15 years of experience in healthcare data, analytics, and market research. She leads Phreesia's Analytics and Insights (AI) and Business Intelligence teams, ensuring effective audience targeting and campaign performance. Her efforts assist clients in delivering relevant health content to millions of patients monthly.
In her role, Patel collaborates with the Product and Data Integration teams to continuously enhance Phreesia's content delivery, focusing on privacy and patient engagement. Phreesia's Senior VP, David Linetsky, acknowledged the significance of Patel's contributions to the company's mission of improving patient care and health outcomes.
Phreesia, a leader in patient intake, outreach, and activation, has been named one of Modern Healthcare’s 2024 Best Places to Work in Healthcare.
This marks the eighth time Phreesia has received this recognition. The award highlights 150 U.S. healthcare companies known for empowering employees to provide high-quality care and services.
Phreesia's SVP of Human Resources, Amy VanDuyn, emphasized the importance of the company's culture and employee engagement. The award is determined based on employee surveys evaluating areas such as culture, leadership, benefits, and job satisfaction.
Dan Peres, President of Modern Healthcare, noted that in the face of economic challenges and evolving work environments, the winners understand the importance of meeting employee needs to ensure business success.
Founded in 2005, Phreesia facilitated 150 million patient visits in 2023, providing digital solutions to enhance patient experience and healthcare outcomes.
Phreesia's Alicia Cowley and Natasha Vega have been named to MM+M's 'Women to Watch' for 2024, highlighting their significant impact on the healthcare marketing industry. Cowley, as Director of Clinical Content, and Vega, as Senior Client Experience Manager, were recognized for their leadership and contributions to Phreesia's vision of empowering patients in their healthcare journey.
Phreesia, Inc. (NYSE: PHR) has announced the release date for its fiscal first quarter 2025 financial results, set for after market trading on Thursday, May 30, 2024. The company will issue a press release and a quarterly stakeholder letter, to be posted on their investor website at ir.phreesia.com. A conference call to discuss the results will take place at 5PM Eastern Time on the same day. Phreesia is a leader in patient activation, enabling approximately 150 million patient visits in 2023 and offering digital solutions to enhance the patient experience and improve healthcare outcomes.
FAQ
What is the current stock price of Phreesia (PHR)?
What is the market cap of Phreesia (PHR)?
What does Phreesia, Inc. do?
What is the Phreesia Platform?
How does Phreesia benefit healthcare organizations?
What are some of Phreesia's recent achievements?
What makes Phreesia's platform scalable and flexible?
Who uses Phreesia's services?
What is Phreesia's approach to patient activation?
How does Phreesia enhance patient-provider interactions?
What are some key features of the Phreesia Platform?